Amberg

• A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults with Type 2 D … Pending
  2024-520068-32-00 6 Type 2 diabetes
• Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad … Pending
  2025-521221-32-00 5 Advanced or Metastatic Non-Small Cell Lung Cancer
• Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col … Pending
  2025-522377-12-00 5 metastatic colorectal cancer
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU … Recruiting
  2023-506414-46-00 5 2022-04-22 High risk patients defined as having at least one of the following ris
• A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E … Recruiting
  2024-518777-34-00 5 2026-02-11 B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
• FUTURE Recruiting
  2024-517573-24-00 4 2025-12-08 Colorectal cancer
• – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici … Recruiting
  2024-519929-38-00 4 2025-10-27 Metastatic Colorectal Cancer without liver metastases
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• A Randomized, Double-blinded, Multicenter, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) i … Recruiting
  2024-516633-12-00 5 2025-06-30 Locally advanced/ metastatic gastroesophageal junction and gastric can
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi … Recruiting
  2023-508076-11-00 5 2025-04-01 Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
• Comparison between ABP 234 and Keytruda® (Pembrolizumab) Recruiting
  2024-514304-14-00 1 2024-10-08 Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a … Recruiting
  2023-505436-35-00 5 2024-06-03 Untreated FLIPI 2-5 Follicular Lymphoma
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac … Recruiting
  2022-502046-28-00 5 2023-12-22 HER2-Positive, PIK3CA Mutated, Locally Advanced or Metastatic Breast C
• MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient … Recruiting
  2022-501810-77-00 5 2023-09-01 Relapsed or Refractory Marginal Zone Lymphoma
• A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults wi … Recruiting
  2022-501187-18-00 5 2023-04-24 a. Diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS)
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 5 2022-11-21 unresectable or metastatic HER2+ colorectal cancer
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 Patients with advanced HER2-negative, hormone receptor positive (HER2n
• Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized, … Recruiting
  2024-512174-10-00 5 2021-11-11 metastatic colorectal cancer
• Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trif … Recruiting
  2024-513723-16-00 4 2021-10-21 metastatic colorectal cancer
• The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli … Recruiting
  2024-512953-26-00 5 2021-07-06 intermediate-stage hepatocellular carcinoma
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer

Showing 1–24 of 38 trials